Polypharmacy among patients with hypertension attending primary healthcare centres

Introduction: Saudi Arabia has several hypertensive patients who require close attention and specialised care for their medications. Polypharmacy is one of the reasons for the failure of patient compliance with antihypertensive medications. Therefore, this study aims to gain a better perspective on polypharmacy in hypertensive patients attending primary healthcare (PHC) centres in Makkah, Saudi Arabia. Methods: This was an observational, cross-sectional, descriptive study of hypertensive patients followed up at 10 PHC centres in Makkah, Saudi Arabia, from 1 July 2019 to 30 June 2022. Frequencies and percentages were used to present categorical data, and Pearson’s χ 2 test was used to measure differences. A P value less than 0.05 was considered statistically significant. Results: A total of 506 patients were included in this study. The mean age of the patients was 60 years, and more than half (69%) were females. Regarding antihypertensive medication use, 64% were on antihypertensive combination therapy, 76% on dual therapy, 21% on triple therapy, and 3% on quadruple therapy. Moreover, 21% of the hypertensive patients were exposed to polypharmacy. There was a significant relationship (P<0.001) between the overall number of chronic medications used per day and the duration of hypertension. Conclusion: More clinical research is needed to identify the impact of polypharmacy on the quality of healthcare in PHC centres in general and hypertensive patients specifically in different regions of Saudi Arabia.

[1]  A. Alsaad,et al.  Medication Adherence Among Multimorbid Patients With Polypharmacy and Its Relation to Social Support at National Guard Primary Health Care Centers, Riyadh , 2022, Cureus.

[2]  A. Alshanberi Recent Updates on Risk and Management Plans Associated with Polypharmacy in Older Population , 2022, Geriatrics.

[3]  H. Alwafi,et al.  Medication Adherence among Patients with Chronic Diseases in Saudi Arabia , 2022, International journal of environmental research and public health.

[4]  F. Farahat,et al.  Quality of care provided to diabetic patients attending primary health care centers in National Guard in Makkah Region, Saudi Arabia , 2022, Journal of family medicine and primary care.

[5]  C. Diaconu,et al.  Polypharmacy in the Management of Arterial Hypertension—Friend or Foe? , 2021, Medicina.

[6]  I. Bougmiza,et al.  Prevalence of polypharmacy and the association with non-communicable diseases in Qatari elderly patients attending primary healthcare centers: A cross-sectional study , 2020, PloS one.

[7]  J. Flack,et al.  Blood pressure and the new ACC/AHA hypertension guidelines. , 2020, Trends in cardiovascular medicine.

[8]  R. Wali,et al.  Patient satisfaction with the implementation of electronic medical Records in the Western Region, Saudi Arabia, 2018 , 2020, BMC Family Practice.

[9]  J. Cohen,et al.  Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts—Results of a Literature Review , 2020, Therapeutics and clinical risk management.

[10]  N. Jones,et al.  Diagnosis and management of hypertension in adults: NICE guideline update 2019. , 2020, The British journal of general practice : the journal of the Royal College of General Practitioners.

[11]  S. Labeeb,et al.  Prevalence and Risk of Polypharmacy among Community-Dwelling, Elderly Kuwaiti Patients , 2019, Medical Principles and Practice.

[12]  S. Alsuwaidan,et al.  A Comprehensive Overview of Polypharmacy in Elderly Patients in Saudi Arabia , 2019, Geriatrics.

[13]  Y. Ouchi,et al.  Trends in Polypharmacy in Japan: A Nationwide Retrospective Study , 2018, Journal of the American Geriatrics Society.

[14]  P. Whelton,et al.  Prevention and Control of Hypertension: JACC Health Promotion Series. , 2018, Journal of the American College of Cardiology.

[15]  A. Krumeich,et al.  Reduction of inappropriate medication in older populations by electronic decision support (the PRIMA-eDS study): a qualitative study of practical implementation in primary care , 2018, BMC Family Practice.

[16]  B. Golomb,et al.  International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action , 2018, Drugs & Aging.

[17]  Tariq M. Alhawassi,et al.  Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia , 2018, BMJ Open.

[18]  K. Johnell,et al.  The epidemiology of polypharmacy in older adults: register-based prospective cohort study , 2018, Clinical epidemiology.

[19]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[20]  Karine Gonçalves Pereira,et al.  Polypharmacy among the elderly: a population-based study. , 2017, Revista brasileira de epidemiologia = Brazilian journal of epidemiology.

[21]  P. Wilkinson,et al.  Primary prevention of cardiovascular disease: A review of contemporary guidance and literature , 2017, JRSM cardiovascular disease.

[22]  L. Ramos,et al.  Polypharmacy and Polymorbidity in Older Adults in Brazil: a public health challenge , 2016, Revista de saude publica.

[23]  S. Assari,et al.  Defining polypharmacy in the elderly: a systematic review protocol , 2016, BMJ Open.

[24]  D. DiPette,et al.  Diabetes and Hypertension: A Comparative Review of Current Guidelines , 2016, Journal of clinical hypertension.

[25]  C. Charlesworth,et al.  Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. , 2015, The journals of gerontology. Series A, Biological sciences and medical sciences.

[26]  P. Nishtala,et al.  Temporal Trends in Polypharmacy and Hyperpolypharmacy in Older New Zealanders over a 9-Year Period: 2005-2013 , 2014, Gerontology.

[27]  Ju-Young Shin,et al.  Prevalence and Predictors of Polypharmacy among Korean Elderly , 2014, PloS one.

[28]  Joseph Hanlon,et al.  Clinical consequences of polypharmacy in elderly , 2014, Expert opinion on drug safety.

[29]  S. Sabzwari,et al.  Polypharmacy in elderly: a cautious trail to tread. , 2013, JPMA. The Journal of the Pakistan Medical Association.

[30]  V. Maio,et al.  Prevalence and Risk of Polypharmacy among the Elderly in an Outpatient Setting , 2010, Drugs & aging.

[31]  Reamer L. Bushardt,et al.  Polypharmacy: Misleading, but manageable , 2008, Clinical interventions in aging.

[32]  Mridula Nair,et al.  Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable , 2007, Expert opinion on drug safety.

[33]  R. Petrella,et al.  Prevalence, Treatment, and Control of Hypertension in Primary Care: Gaps, Trends, and Opportunities , 2007, Journal of clinical hypertension.

[34]  E. Ofili Dispelling the Myth of “Aggressive” Antihypertensive Therapy , 2006, Journal of clinical hypertension.

[35]  Katrina M. Krause,et al.  Is There Time for Management of Patients With Chronic Diseases in Primary Care? , 2005, The Annals of Family Medicine.

[36]  Loida D Nguyen,et al.  Hypertension management: an update. , 2010, American health & drug benefits.